USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA); Guam (USA); Puerto Rico (USA); Virgin Islands (USA); Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta; British Columbia; Manitoba; New Brunswick; Newfoundland and Labrador; Northwest Territories; Nova Scotia; Nunavut; Ontario; Prince Edward Island; Quebec; Saskatchewan; Yukon
GrantRegions Object ( [regions] => Array ( ) [is_initialized] => [error_messages] => Array ( ) [qm] => QueryManager Object ( [is_debug] => [conn] => mysqli Object ( [affected_rows] => 9 [client_info] => mysqlnd 5.0.12-dev - 20150407 - $Id: 3591daad22de08524295e1bd073aceeff11e6579 $ [client_version] => 50012 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [error_list] => Array ( ) [field_count] => 2 [host_info] => 172.16.38.157 via TCP/IP [info] => [insert_id] => 0 [server_info] => 5.5.5-10.5.18-MariaDB [server_version] => 100518 [stat] => Uptime: 3105723 Threads: 256 Questions: 531017147 Slow queries: 1306 Opens: 118365 Open tables: 405 Queries per second avg: 170.980 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 86193931 [warning_count] => 0 ) ) [has_regions] => 1 [state_names] => Array (  => Alabama;  => Alaska;  => Arizona;  => Arkansas;  => California;  => Colorado;  => Connecticut;  => Delaware;  => Florida;  => Georgia;  => Hawaii;  => Idaho;  => Illinois;  => Indiana;  => Iowa;  => Kansas;  => Kentucky;  => Louisiana;  => Maine;  => Maryland;  => Massachusetts;  => Michigan;  => Minnesota;  => Mississippi;  => Missouri;  => Montana;  => Nebraska;  => Nevada;  => New Hampshire;  => New Jersey;  => New Mexico;  => New York;  => North Carolina;  => North Dakota;  => New York City;  => Ohio;  => Oklahoma;  => Oregon;  => Pennsylvania;  => Rhode Island;  => South Carolina;  => South Dakota;  => Tennessee;  => Texas;  => Utah;  => Vermont;  => Virginia;  => Washington;  => Washington, DC;  => West Virginia;  => Wisconsin;  => Wyoming; ) [province_names] => Array (  => Alberta;  => British Columbia;  => Manitoba;  => New Brunswick;  => Newfoundland and Labrador;  => Northwest Territories;  => Nova Scotia;  => Nunavut;  => Ontario;  => Prince Edward Island;  => Quebec;  => Saskatchewan;  => Yukon; ) [country_names] => Array (  => American Samoa (USA)  => The Federated States of Micronesia (USA)  => Guam (USA)  => Marshall Islands (USA)  => Puerto Rico (USA)  => Republic of Palau (USA)  => Virgin Islands (USA)  => Northern Mariana Islands (USA) ) [is_israel] => 1 [territories] => Array (  => American Samoa (USA);  => Guam (USA);  => Puerto Rico (USA);  => Virgin Islands (USA);  => Northern Mariana Islands (USA); ) [free_associations] => Array (  => The Federated States of Micronesia (USA)  => Marshall Islands (USA)  => Republic of Palau (USA) ) )
International country outside of the USA, Israel and Canada.
Grants to USA, Canada, and International researchers and clinicians at IHEs, nonprofit and for-profit organizations, and academic medical centers for research related to cognitive disorders. Applicants must submit a Letter of Intent prior to submitting a full proposal. Funding is intended to address the challenges related to frontotemporal dementia (FTD), build on emerging scientific understanding of biological mechanisms underlying FTD, provide critical funding for early-stage clinical trials, and stimulate the field to develop new therapies for FTD disorders.
The Treat FTD fund aims to support programs testing drugs or devices for FTD disorders while building clinical data around FTD mechanisms in human disease and corresponding biomarker endpoints in response to treatment. The fund aims to de-risk clinical development programs by supporting clinical trials generating data leading to clear go/no-go decisions and if positive, sufficient data to encourage follow on funding of the approach. Programs will be considered that test novel or repurposed drug candidates or devices in phase 0, 1 or 2 clinical trials for FTD disorders, led by academic researchers or biotechnology companies, worldwide. Both disease-modifying and symptomatic approaches will be considered.
The RFP seeks to support clinical trials with:
Although the strongest proposals will contain all of these aspects, any approaches with a sound biological rationale and well-justified outcome measures for the patient population will be considered.
Proposals without an identified target will also be considered but a clear connection to FTD should be described. Biological areas of interest include, but are not limited to:
The drug should have completed or be in the process of completing IND-enabling studies at the time of application. If IND-enabling work is in progress, any award would be contingent upon getting an IND from the FDA and a full review of the data package.
Estimated Size of Grant:
Apply online: https://addf.fluxx.io/user_sessions/new
For scientific inquiries, please contact:
Meriel Owen, PhD, Assistant Director, ADDF
Debra Niehoff, PhD, Research Manager, AFTD
For policies, contracts and terms, and IT related inquiries, please contact:
Grants and Mission-Related Investments Team
Alzheimer's Drug Discovery Foundation
57 West 57th Street, Suite 904
New York, NY 10019